PolyPhotonix Celebrates Ten Years of Operations

PolyPhotonix Celebrates Ten Years of Operations
PolyPhotonix Ltd is celebrating its 10 year anniversary. During that time, the company has successfully developed a treatment for one of the most common causes of blindness in the world – Diabetic Retinopathy.

PolyPhotonix Ltd is pleased to announce that it has recently reached a milestone of ten years in operation. During that time, PolyPhotonix has developed a home-based, non-invasive, monitored treatment for one of the principal causes of blindness in the western world, Diabetic Retinopathy (DR), and Diabetic Macular Oedema (DMO). PolyPhotonix is now bringing this innovative medtech wearable device to the world with operations and regulatory approval in France, Brazil, Hong Kong, Oman, Portugal, U.S.A, and other places.

Patients have now used the mask successfully for over 1.5 million hours (the mask actually records individual patient use time). The aim is to make Noctura 400 available to everyone who could benefit from the treatment by getting it established as a standard NHS treatment in the UK. The NHS is evaluating the treatment for adoption in a number of hospitals.

The Noctura 400 Sleep Mask, offers a novel and innovative treatment for diabetic patients with these severe sight complications, and will significantly change the patient experience and cost basis compared with current treatments. Noctura 400 can be administered to late-stage patients as per current interventions, and also enables early-stage preventative treatment to a larger patient group before expensive clinical procedures are necessary.

Noctura 400 has been designed as a treatment to prevent and slow the progression of diabetic retinopathy and retain visual acuity. Today the most common treatments for DR are highly invasive and expensive.   Laser photocoagulation is a treatment that cauterises the affected and damaged blood vessels in the retina, but the procedure is not a cure and only delays to a limited extent the inevitable progress of the disease. As it also irreversibly damages photoreceptors, long term treatment with laser photocoagulation will lead to loss of sight. The treatment for the later-stage disease is an injection directly into the eye (intravitreal injection) of anti-VEGF drugs and currently costs more than £6,500 per eye per year. This is simply too expensive for many patients worldwide.

The technology offers an alternative, non-invasive treatment option easily adopted (at significantly lower comparative cost base) within the current treatment pathway. Noctura 400, with its in-built monitoring and compliance functionality, is designed explicitly as a monitored home-based therapy that will form the basis of a new care pathway, bridging the gap between primary and secondary care. Future adoption of the PPX technology for the preventative care of early-stage DR patients offers a route to significantly reducing numbers of patients referred to the hospital eye service. Clinical trial and study data have demonstrated that Noctura 400 is safe and has the potential to treat this condition at a fraction of the cost, creating the opportunity to provide affordable and non-invasive treatment to the millions who are affected across the globe.

Additional details are available at www.noctura.com

Media Contact
Company Name: PolyPhotonix Ltd
Contact Person: Mr Burns
Email: Send Email
Phone: 01740 625555
Address:Explorer 2/F2, NETPark, Thomas Wright Way
City: Durham
State: Sedgefield TS21 3FF
Country: United Kingdom
Website: www.polyphotonix.com


Posted

in

by

Tags: